Last reviewed · How we verify
Ranquilon
At a glance
| Generic name | Ranquilon |
|---|---|
| Also known as | GB-115, N-(6-phenylhexanoyl)glycyl-L-tryptophan amide, 6-phenylhexanoyl)glycyl-L-tryptophan amide |
| Sponsor | Valenta Pharm JSC |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders (PHASE4)
- A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ranquilon CI brief — competitive landscape report
- Ranquilon updates RSS · CI watch RSS
- Valenta Pharm JSC portfolio CI